Q4 2024 Vistin Pharma ASA Earnings Call Transcript
Key Points
- Vistin Pharma ASA (STU:VP4) reported a strong operational performance with a 11% increase in sales volume in Q4 2024 compared to Q4 2023.
- The company achieved an all-time high EBITDA of NOK104 million for the full year 2024, representing a 21% increase from the previous year.
- Vistin Pharma ASA maintains a strong balance sheet with an equity ratio of 80% and a net cash position of NOK13 million as of year-end.
- The company has a long-term renewable energy supply agreement with Statkraft until 2032, ensuring predictable power prices and 100% green renewable hydropower.
- Vistin Pharma ASA is strategically positioned in the growing global Metformin market, with a 10% market share and expected market growth of 4% to 6% annually.
- The full-year revenue for 2024 was slightly lower at NOK430 million compared to NOK438 million in 2023.
- There was an unplanned production stop on line two in Q1 2024, affecting the sales volume for the year.
- The company faced headwinds from a stronger USD versus NOK, impacting raw material costs.
- Realized prices were generally lower due to decreased raw material costs post-pandemic.
- The company has an incentive plan expense of NOK2 million booked in the fourth quarter, impacting financial results.
Thank you, and welcome everyone to this fourth quarter and the preliminary full-year results presentation of Vistin Pharma. My name is Magnus Tolleshaug, CEO of the company. And with me today, in today's call, I have our CFO, Mr. Alexander Karlsen. I will now go through the highlights.
The revenue of the fourth quarter ended at NOK114 million versus NOK111 million in the fourth quarter of 2023. A strong operational performance resulted in more volumes available for sale in the quarter. Plus 11% versus the fourth quarter 2023.
The 2024 full-year revenue ended at NOK430 million compared to NOK438 million last year. The sales volume increased by 4% in 2024, even with an unplanned stop in on line two in the first quarter where our line two was idle for several weeks as previously communicated.
The EBITDA for the fourth quarter ended at NOK28 million versus NOK25 million in the fourth quarter of 2023. The EBITDA was positively affected by increased sales volume and good cost control in the quarter.
We ended at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
